Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864076 | 0.86 | ADRB1 (0.38) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL22864143 | 0.86 | ADRB2 (0.45) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL24630970 | 0.77 | IDO1 (0.59) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL22864082 | 0.76 | ADRB2 (0.43) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL24630966 | 0.76 | ADRB2 (0.43) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL22864087 | 0.76 | ADRB2 (0.43) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL28724409 | 0.76 | ADRB2 (0.43) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL22864253 | 0.74 | IDO1 (0.60) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL24630962 | 0.72 | ROCK2 (0.50) | HIF1AADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL12110234 | 0.72 | METAP2 (0.46) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | HIF1A 2371/4885ADRB2 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.